Te Ahumairangi Investment Management Ltd Boosts Holdings in DaVita Inc. $DVA

Te Ahumairangi Investment Management Ltd raised its position in shares of DaVita Inc. (NYSE:DVA) by 39.1% during the second quarter, HoldingsChannel reports. The fund owned 58,861 shares of the company’s stock after acquiring an additional 16,543 shares during the quarter. DaVita accounts for approximately 1.5% of Te Ahumairangi Investment Management Ltd’s investment portfolio, making the stock its 16th largest holding. Te Ahumairangi Investment Management Ltd’s holdings in DaVita were worth $8,385,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Doma Perpetual Capital Management LLC boosted its stake in shares of DaVita by 172.3% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after purchasing an additional 182,476 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in DaVita in the second quarter worth about $21,554,000. Northern Trust Corp boosted its position in shares of DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares during the period. Nuveen LLC bought a new position in shares of DaVita during the first quarter valued at approximately $20,218,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of DaVita in the second quarter worth approximately $15,902,000. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Cowen restated a “hold” rating on shares of DaVita in a report on Monday, November 3rd. TD Cowen decreased their target price on DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research report on Monday, November 3rd. Bank of America cut their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Barclays lowered their price objective on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, DaVita has a consensus rating of “Reduce” and a consensus target price of $148.00.

DaVita Trading Up 1.7%

Shares of DVA stock opened at $121.48 on Wednesday. DaVita Inc. has a twelve month low of $113.97 and a twelve month high of $179.60. The stock has a fifty day simple moving average of $125.58 and a two-hundred day simple moving average of $134.12. The stock has a market capitalization of $8.58 billion, a price-to-earnings ratio of 12.51, a P/E/G ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last released its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. During the same quarter in the previous year, the firm earned $2.59 earnings per share. The business’s revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.